Uncover the Mystery of Epilepsy

Posted by: Doctor Medical  :  Category: Health, Health News

545thm

“Put harshly, we need more of a cancerlike sensibility around epilepsy,” Newsweek Editor Jon Meacham writes in the April 20 cover, “The Mystery of Epilepsy” (on newsstands Monday, April 13). “We cannot usually see our friends’ cancer, but we do not hesitate to invest the search for a cure for different cancers with the utmost cultural and political importance. We must now do the same with epilepsy.”

Meacham writes that the toll of epilepsy has been overlooked — and the research underfunded — for too long. Public and private funding for research lag far behind other neurological afflictions. “It is time to remedy that gap, and to raise epilepsy to the front ranks of public and medical concern,” he writes.

“Epilepsy in America is as common as breast cancer, and takes as many lives,” Meacham writes. A mysterious and widely misunderstood affliction, epilepsy is a disorder in which the brain produces sudden bursts of electrical energy that can interfere with a person’s consciousness, movements or sensations.

By some estimates, the mortality rate for people with epilepsy is two to three times higher — and the risk of sudden death is 24 times greater — than that of the general population. Yet epilepsy still receives too little attention, either from the medical community or the public at large. “One reason is that advances in drug treatments have created the popular impression that epilepsy is now an essentially manageable condition,” Meacham writes.

“Most people with epilepsy are not in a constant state of seizure — they are, rather, in perpetual but quiet danger — their condition can appear less serious than it truly is. It is all too human, but all too true, that a problem, including the problem of a serious medical affliction, stays out of mind when it is out of sight.”

Keppra XR Dosage Strength Tablets to Combat Partial One-Set Seizures

Posted by: Doctor Medical  :  Category: Health, Health News, Medication

515thm

Keppra has improved on its dosage, unveiling the Once-daily Keppra XR extended-release tablets which are now available in a new dosage strength, 750 mg. This enables doctors to simplify patients’ treatment plans by decreasing the number of tablets they take each day.

According to studies published in Epilepsy & Behavior and Neurology, patients are more likely to adhere to their medication regimen when it is taken once daily, and therefore may be more likely to reach the goal of epilepsy therapy–seizure freedom with minimal side effects.

Keppra XR was approved by the U.S. Food and Drug Administration (FDA) based on data from an international clinical study of 158 epilepsy patients with partial-onset seizures who added 1,000 mg of Keppra XR or placebo to their other epilepsy medications once daily. The study consisted of an 8-week baseline period followed by a 12-week treatment period.

  • The study showed that 10.1 percent of Keppra XR(TM) patients experienced complete partial-onset seizure freedom vs. 1.3 percent in the placebo group over the treatment period.
  • Keppra XR patients experienced a 46.1 median percent reduction in weekly partial-onset seizure frequency versus 33.4 percent in the placebo group.

Keppra XR is also available in 500 mg tablet strength. Data presented at last year’s American Epilepsy Society meeting demonstrated that taking two 750 mg levetiracetam extended-release tablets is the same as taking three 500 mg extended-release tablets.

Treatment with Keppra XR should be initiated with a dose of 1,000 mg once daily. The daily dosage may be adjusted in increments of 1,000 mg every two weeks, to a maximum recommended dose of 3,000 mg per day.

(Source) Press